VEGF-A
Assets acting on this target.
- Class
- VEGF-A inhibitor
- Pathway
- VEGF-A / VEGFR angiogenic signaling
VEGF-A (vascular endothelial growth factor A) is a signaling protein that binds receptors on blood vessel lining cells, driving new vessel formation and increasing vessel permeability. In the eye, excessive VEGF-A activity underlies several blinding conditions, including wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy, where abnormal, leaky vessels grow beneath or within the retina and cause fluid accumulation, hemorrhage, and progressive vision loss. Neutralizing VEGF-A reduces this abnormal vascularization and vascular leakage, which is why anti-VEGF therapy has become a mainstay of retinal disease management. Conventional treatment requires repeated intraocular injections of antibody-based drugs because these proteins are cleared over weeks to months. Gene therapy approaches address this limitation by delivering, via a single injection, a viral vector containing genetic instructions for retinal cells to continuously produce their own anti-VEGF protein, in this case a secreted antibody fragment. The goal is durable, self-sustaining suppression of VEGF-A activity within the eye, potentially reducing the treatment burden associated with chronic dosing while achieving the same underlying biological effect as injected anti-VEGF biologics.
By indication
Related mechanisms
VEGF-A drugs compared
39 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| AfliberceptEylea | Bayer, Regeneron Pharmaceuticals | fusion protein | Approved | Approved in Age-Related Macular Degeneration; Approved in Diabetic Macular Edema; Approved in Wet Age-Related Macular Degeneration |
| aflibercept-abzv (Enzeevu)Enzeevu | Sandoz Group AG | fusion protein | Approved | Approved in Age-Related Macular Degeneration; Approved in Diabetic Macular Edema |
| aflibercept-ayyh (Pavblu)Pavblu | Amgen | fusion protein | Approved | Approved in Age-Related Macular Degeneration; Approved in Diabetic Macular Edema; Approved in Wet Age-Related Macular Degeneration |
| aflibercept-boav (Eydenzelt)Eydenzelt | Celltrion | fusion protein | Approved | Approved in Age-Related Macular Degeneration; Approved in Diabetic Macular Edema; Approved in Wet Age-Related Macular Degeneration |
| aflibercept-jbvf (Yesafili)Yesafili | Biocon Biologics | fusion protein | Approved | Approved in Age-Related Macular Degeneration; Approved in Diabetic Macular Edema; Approved in Wet Age-Related Macular Degeneration |
| aflibercept-mrbb (Ahzantive)Ahzantive | Formycon AG, Klinge Biopharma GmbH, Valorum Biologics LLC | fusion protein | Approved | Approved in Age-Related Macular Degeneration; Approved in Diabetic Macular Edema; Approved in Wet Age-Related Macular Degeneration |
| aflibercept-yszy (Opuviz)Opuviz | Harrow, Inc., Samsung Bioepis | fusion protein | Approved | Approved in Age-Related Macular Degeneration; Approved in Diabetic Macular Edema; Approved in Wet Age-Related Macular Degeneration |
| Alymsys (bevacizumab-maly) | Amneal Pharmaceuticals | monoclonal antibody | Approved | Approved in Advanced Metastatic Colorectal Cancer; Approved in Cervical Cancer; Approved in Colorectal Cancer; Approved in Glioblastoma; Approved in Metastatic Colorectal Cancer; Approved in Non-Small Cell Lung Cancer; Approved in Recurrent Glioblastoma; Approved in Renal Cell Carcinoma |
| BAT1706Avzivi | BeOne Medicines, Bio-Thera Solutions, Sandoz Group AG | monoclonal antibody | Approved | Approved in Cervical Cancer; Approved in Colorectal Cancer; Approved in Glioblastoma; Approved in Non-Small Cell Lung Cancer; Approved in Ovarian Cancer; Approved in Renal Cell Carcinoma |
| Bevacizumab | Roche | monoclonal antibody | Approved | Approved in Cervical Cancer; Approved in Colorectal Cancer; Approved in Hepatocellular Carcinoma; Approved in Metastatic Colorectal Cancer; Approved in Non-Small Cell Lung Cancer; Approved in Ovarian Cancer; Approved in Recurrent Glioblastoma; Approved in Renal Cell Carcinoma |
| bevacizumab-awwbMVASI | Amgen, Daiichi Sankyo | monoclonal antibody | Approved | Approved in Advanced Metastatic Colorectal Cancer; Approved in Cervical Cancer; Approved in Colorectal Cancer; Approved in Metastatic Colorectal Cancer; Approved in Non-Small Cell Lung Cancer; Approved in Recurrent Glioblastoma; Approved in Renal Cell Carcinoma |
| Brolucizumab-Dbll | China Medical System, Novartis | antibody fragment (scFv) | Approved | Approved in Age-Related Macular Degeneration; Approved in Diabetic Macular Edema; Approved in Wet Age-Related Macular Degeneration |
| Jobevne (bevacizumab-nwgd) | Biocon, Biocon Biologics | monoclonal antibody | Approved | Approved in Advanced Metastatic Colorectal Cancer; Approved in Cervical Cancer; Approved in Colorectal Cancer; Approved in Metastatic Colorectal Cancer; Approved in Non-Small Cell Lung Cancer; Approved in Ovarian Cancer; Approved in Recurrent Glioblastoma; Approved in Renal Cell Carcinoma |
| RanibizumabLucentis | Novartis, Roche | antibody fragment | Approved | Approved in Age-Related Macular Degeneration; Approved in Diabetic Macular Edema; Approved in Wet Age-Related Macular Degeneration |
| ranibizumab-eqrn (Cimerli)Cimerli | Sandoz Group AG | monoclonal antibody | Approved | Approved in Age-Related Macular Degeneration; Approved in Diabetic Macular Edema; Approved in Wet Age-Related Macular Degeneration |
| ranibizumab-hkdz (Ranluspec)Ranluspec | Lupin Limited, Sandoz Group AG | monoclonal antibody | Approved | Approved in Age-Related Macular Degeneration; Approved in Diabetic Macular Edema |
| ranibizumab-leyk (Nufymco)Nufymco | Bioeq AG, Formycon AG, Zydus Lifesciences | monoclonal antibody | Approved | Approved in Age-Related Macular Degeneration; Approved in Diabetic Macular Edema; Approved in Wet Age-Related Macular Degeneration |
| ranibizumab-nuna (Byooviz)Byooviz | Harrow, Inc., Samsung Bioepis | monoclonal antibody | Approved | Approved in Age-Related Macular Degeneration; Approved in Wet Age-Related Macular Degeneration |
| Vegzelma (bevacizumab-adcd) | Celltrion | monoclonal antibody | Approved | Approved in Advanced Metastatic Colorectal Cancer; Approved in Cervical Cancer; Approved in Colorectal Cancer; Approved in Metastatic Colorectal Cancer; Approved in Non-Small Cell Lung Cancer; Approved in Ovarian Cancer; Approved in Recurrent Glioblastoma; Approved in Renal Cell Carcinoma |
| Zirabev (bevacizumab-bvzr)Zirabev | Pfizer | monoclonal antibody | Approved | Approved in Advanced Metastatic Colorectal Cancer; Approved in Cervical Cancer; Approved in Colorectal Cancer; Approved in Metastatic Colorectal Cancer; Approved in Non-Small Cell Lung Cancer; Approved in Recurrent Glioblastoma; Approved in Renal Cell Carcinoma |
| BAT5906 | Bio-Thera Solutions | monoclonal antibody | Phase 3 | Phase 3 in Age-Related Macular Degeneration |
| CKD-701Lucenbies | Chong Kun Dang Pharmaceutical | monoclonal antibody | Phase 3 | Phase 3 in Age-Related Macular Degeneration |
| HD204 | Intas Pharmaceuticals, Prestige Biopharma Limited | monoclonal antibody | Phase 3 | Phase 3 in Non-Small Cell Lung Cancer |
| HLX04Hanbeitai | Shanghai Henlius Biotech | monoclonal antibody | Phase 3 | Phase 3 in Colorectal Cancer; Phase 3 in Non-Small Cell Lung Cancer |
| HLX04-O | Essex Bio-Technology Limited, Shanghai Henlius Biotech | monoclonal antibody | Phase 3 | Phase 3 in Age-Related Macular Degeneration |
| IBI305 | Innovent Biologics | monoclonal antibody | Phase 3 | Phase 3 in Non-Small Cell Lung Cancer; Phase 2 in Colorectal Cancer |
| LY01008 | Luye Pharma Group | monoclonal antibody | Phase 3 | Phase 3 in Non-Small Cell Lung Cancer; Phase 1 in Colorectal Cancer |
| Ranibizumab (Ximluci)Ximluci | STADA Arzneimittel, Xbrane Biopharma AB | monoclonal antibody | Phase 3 | Phase 3 in Age-Related Macular Degeneration |
| Surabgene lomparvovec | AbbVie, REGENXBIO Inc. | AAV gene therapy | Phase 3 | Phase 3 in Age-Related Macular Degeneration |
| Tarcocimab tedromer | Kodiak Sciences Inc. | monoclonal antibody-biopolymer conjugate | Phase 3 | Phase 3 in Age-Related Macular Degeneration; Phase 3 in Wet Age-Related Macular Degeneration |
| MW02 | Mabwell Bioscience, Pyxis Oncology | monoclonal antibody | Phase 2/3 | Phase 2/3 in Age-Related Macular Degeneration |
| Ranibizumab (Rimmyrah)Rimmyrah | Qilu Pharmaceutical | monoclonal antibody | Phase 1 | Phase 1 in Age-Related Macular Degeneration |
| Aflibercept (Afiveg)Afiveg | Alvotech, STADA Arzneimittel | fusion protein | Stage not recorded | Not recorded |
| Aflibercept (Eyluxvi)Eyluxvi | Alteogen Inc., Biolitec Pharma | fusion protein | Stage not recorded | Not recorded |
| Aflibercept (Mynzepli)Mynzepli | Advanz Pharma, Alvotech | fusion protein | Stage not recorded | Not recorded |
| Aflibercept (Vgenfli)Vgenfli | Polpharma S.A., Sam Chun Dang Pharm. Co., Ltd. | fusion protein | Stage not recorded | Not recorded |
| Ranibizumab (Ranivisio)Ranivisio | Midas Pharma GmbH | monoclonal antibody | Stage not recorded | Not recorded |
| Ranibizumab (Rexatilux)Rexatilux | Intas Pharmaceuticals | monoclonal antibody | Stage not recorded | Not recorded |
| Telbermin | Newron Sweden AB | recombinant protein | Discontinued | Not recorded |